Koers Bachem Holding AG Swiss Exchange
Aandelen
BANB
CH0012530207
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 649 mln. 712 mln. 667 mln. | Omzet 2025 * | 823 mln. 903 mln. 846 mln. | Marktkapitalisatie | 6,02 mld. 6,61 mld. 6,19 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 127 mln. 139 mln. 131 mln. | Nettowinst (verlies) 2025 * | 160 mln. 176 mln. 165 mln. | EV/omzet 2024 * | 9,12 x |
Nettoliquiditeiten 2024 * | 104 mln. 114 mln. 107 mln. | Nettoschuld 2025 * | 58,76 mln. 64,52 mln. 60,43 mln. | EV/omzet 2025 * | 7,39 x |
K/w-verhouding 2024 * |
48
x | K/w-verhouding 2025 * |
37,4
x | Werknemers | 2.006 |
Dividendrendement 2024 * |
1,07% | Dividendrendement 2025 * |
1,12% | Vrij verhandelbaar | 94,31% |
Recentste transcriptie over Bachem Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 01-01-19 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 01-02-21 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 25-04-12 |
Director/Board Member | 51 | 13-04-11 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.15% | 18 M€ | +2,84% | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,78% | 41,71 mld. | |
+47,70% | 41,56 mld. | |
+4,01% | 39,74 mld. | |
-15,14% | 25,61 mld. | |
+3,16% | 24,26 mld. | |
-24,08% | 18,55 mld. | |
-2,67% | 11,93 mld. | |
+24,76% | 11,93 mld. | |
+7,01% | 10,91 mld. |